Two out of the three core focus indications are funded to completion.
There are challenges but there are also options for funding, potential positive data and a significantly improved SP, (which also brings benefits for funding). The challenges around funding is noted but talking about insolvent trading is a misleading distraction.
Ann: EVT801 preclinical data published, page-27
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)